Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIK1 | P57059 | 1/20 | 0.82 |
| ▸ | MELK | Q14680 | 1/20 | 0.82 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.82 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.82 |
| ▸ | LCK | P06239 | 13/20 | 0.59 |
| ▸ | SRC | P12931 | 11/20 | 0.59 |
| ▸ | KDR | P35968 | 11/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.59 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17537426 | 0.94 | SIK1 (0.72) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL29440265 | 0.90 | SIK1 (1.00) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL15271960 | 0.90 | SIK1 (1.00) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL17537430 | 0.87 | SIK1 (0.62) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL19227474 | 0.86 | LCK (0.79) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL17537405 | 0.85 | SIK1 (0.90) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL17509519 | 0.82 | SIK1 (0.85) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL19224078 | 0.82 | SIK1 (0.85) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL19224077 | 0.82 | SIK1 (0.85) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL21337898 | 0.81 | SIK1 (0.84) | SIK1MELKSIK2SIK3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-29 | — | — | US | disclosed |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200338087-A9 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200179387-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-11 | — | — | US | disclosed |
| US-20190343842-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-10265321-B2 | Uses of salt-inducible kinase (SIK) inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180221379-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180221379-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20170224700-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170224700-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343842-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK3, SIK2 | SIK1 1/4885MELK 361/4885SIK2 3/4885 |
| US-20200179387-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | SOST, SIK2, SIK1 | SIK1 3/4885MELK 499/4885SIK2 2/4885 |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | SOST, SIK2, SIK1 | SIK1 3/4885MELK 499/4885SIK2 2/4885 |
| US-10265321-B2 | Uses of salt-inducible kinase (SIK) inhibitors | SIK1, SIK2, SIK3 | SIK1 1/4885MELK 332/4885SIK2 2/4885 |
| US-20170224700-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK2, SIK3 | SIK1 1/4885MELK 332/4885SIK2 2/4885 |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | SOST, SIK2, SIK1 | SIK1 3/4885MELK 499/4885SIK2 2/4885 |
| US-20200338087-A9 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK3, SIK2 | SIK1 1/4885MELK 361/4885SIK2 3/4885 |
| US-20180221379-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK2, SIK3 | SIK1 1/4885MELK 332/4885SIK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.